Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a subset of claims (IV anesthetic use and induction of general anesthesia) is supported by the provided label text. Several other claims are not supported by the supplied prescribing information (e.g., procedural sedation use and salt-formulation details).
Category Scores
Accurate Statements
Etomidate is an IV anesthetic.
DESCRIPTION and INDICATIONS AND USAGE indicate intravenous injection for anesthesia induction.
Etomidate is used for induction of general anesthesia.
DESCRIPTION: 'intended for the induction of general anesthesia by intravenous injection.' INDICATIONS AND USAGE: 'indicated ... for the induction of general anesthesia.'
The most familiar brand name historically associated with etomidate is Amidate.
Label supports the presence of the brand name AMIDATE (Etomidate Injection, USP) but does not support the 'historically most familiar' framing.
Unsupported Statements
Etomidate’s generic name is etomidate (the drug’s international nonproprietary name, INN).
No INN/generic-name statement present in the supplied label sections.
Etomidate is also commonly written as etomidate in prescribing and labeling.
No statement about common spelling/usage in the supplied label sections.
Etomidate is used as part of procedural sedation in some clinical settings.
No procedural sedation indication mentioned in the supplied label sections.
Etomidate is often specified as etomidate with a salt form in the product formulation (commonly etomidate hydrochloride), depending on the exact manufacturer and presentation.
No salt-formulation (e.g., hydrochloride) details present in the supplied label text.
Contradictions
Important Omissions
FDA-required safety/label sections (e.g., contraindications, boxed warnings, warnings/precautions, adverse reactions, dosing/administration details) were not provided in the prompt, preventing assessment of many safety-related alignment aspects.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are unsupported by the supplied label text (procedural sedation use; salt-formulation details; INN/generic-name statements). While no direct contradictions are identifiable from the limited provided sections, the lack of label support for these statements and missing key safety sections increases the risk of misalignment with approved labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple extracted claims are not supported by the provided label text (especially procedural sedation and salt-formulation details), and generic/INN-related statements are not evidenced.
Suggested Improvement
Restrict claims to statements explicitly supported by the supplied label sections (e.g., IV induction of general anesthesia; brand/product name AMIDATE and that the drug is etomidate). Do not include procedural sedation or formulation-salt claims unless present in the FDA-approved label text provided.